A decade of controversy: Balancing policy with evidence in the regulation of prescription Drug advertising

American Journal of Public Health

Volumn 100, Issue 1, 2010, Pages 24-32

  Frosch, Dominick L ^a,b   Grande, David ^b   Tarn, Derjung M ^a   Kravitz, Richard L ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRESCRIPTION DRUG;

ADVERTIZING; ARTICLE; ATTITUDE TO HEALTH; CONSUMER; DRUG LEGISLATION; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; HUMAN; LEGAL ASPECT; MASS MEDIUM; STANDARD; UNITED STATES;

ADVERTISING AS TOPIC; CONSUMER PARTICIPATION; GOVERNMENT REGULATION; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; LEGISLATION, DRUG; MASS MEDIA; PRESCRIPTION DRUGS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 74049146377     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2008.153767     Document Type: Article

References (75)

1. Health IMS. Total US promotional spend by type, 2008. Available at: http://www.imshealth.com/deployedfiles/imshealth.com/deployedfiles/imshealth/ Global/Content/StaticFile/Top-Line-Data/U.S.-Promo-Spend-Data-2008.pdf. Accessed September 10, 2009.
2. 2. Donohue J. A history of drug advertising: the evolving roles of consumers and consumer protection. Milbank Q. 2006;84(4):659-699. (Pubitemid 44684656)
3. 3. Donohue JM, Cevasco M, Rosenthal MB. A decade of direct-to-consumer advertising of prescription drugs. N Engl J Med 2007;357(7):673-681. (Pubitemid 47267237)
4. Shuchman M Drug risks and free speech-can Congress ban consumer drug ads? N Engl J Med 2007;356(22):2236-2239.
5. Waxman HA. A history of adverse drug experiences: Congress had ample evidence to support restrictions on the promotion of prescription drugs. Food Drug Law J. 2003;58(3):299-312.
6. Vladeck D. The difficult case of direct-to-consumer advertising. Loyola Los Angel Law Rev. 2008;41(1):259-296.
7. Richwine L. US Democrat backs advertising limits for medicines. Reuters. December 8, 2008. Available at: http://www.reuters.com/article/rbssHealthcare- News/idUSN0850286920081208. Accessed January 12, 2009.
8. 8. Frosch DL, Kaplan RM. Shared decision making in clinical medicine: past research and future directions. Am J Prev Med. 1999;17(4):285-294. (Pubitemid 29505475)
9. Antony P. PhRMA chief medical officer testifies on DTC advertising. 2005. Available at: http://www.phrma.org/publications/testimony-and-official- submissions/phrma-chief-medical-officer-testifies-on-direct-to-consumer- advertising. Accessed Jaunuary 16, 2009.
10. Lipsky MS, Taylor CA The opinions and experiences of family physicians regarding direct-to-consumer advertising. J Fam Pract. 1997;45(6):495-499.
11. Murray E, Lo B, Pollack L, Donelan K, Lee K. Direct-to-consumer advertising: physicians' views of its effects on quality of care and the doctor-patient relationship. J Am Board Fam Pract. 2003 ; 16(6) : 513-524.
12. 12. Weissman JS, Blumenthal D, Silk AJ. Physicians report on patient encounters involving direct-to-consumer advertising. Health Aff (Millwood). 2004(Suppl Web Exclusives):W4-219-233. (Pubitemid 39302585)
13. Murray E, Lo B, Pollack L, Donelan K, Lee K. Direct-to-consumer advertising: public perceptions of its effects on health behaviors, health care, and the doctorpatient relationship. J Am Board Fam Pract 2004;17(1):6-18.
14. 14. Deshpande A, Menon A, Petri M III, Zirikhan G. Direct-to-consumer advertising and its utility in health care decision making: a consumer perspective. J Health Commun. 2004;9(6):499-513. (Pubitemid 40115879)
15. 15.Allison-OtteyS,RuffinK,AllisonK,OtteyCC.Assessingtheimpactofdirect-to- consumeradvertisementsontheAApatient: amultisitesurveyofpatientsduringtheofficevisit.JNailMedAssoc.2003;95(2):120-131. (Pubitemid37099553)
16. Robinson AR, Hohmann KB, Rifkin JI, et al. Direct-to-consumer pharmaceutical advertising: physician and public opinion and potential effects on the physician-patient relationship. Arch Intern Med. 2004;164(4):427-432.
17. Bell RA Wilkes MS, Kravitz RL. The educational value of consumer-targeted prescription drug print advertising. J Fam Pract. 2000;49(12):1092-1098.
18. Frosch DL, Krueger PM, Hornik RC, Cronholm PF, Barg FK. Creating demand for prescription drugs: a content analysis of television direct-to-consumer advertising. Ann Fam Med. 2007;5(1):6-13.
19. Macias W, Pashupati K, Lewis LS. A wonderful life or diarrhea and dry mouth? Policy issues of direct-to-consumer drug advertising on television. Health Commun. 2007;22(3):241-252.
20. 20. Woloshin S, Schwartz LM, Tremmel J, Welch HG. Direct-to-consumer advertisements for prescription drugs: what are Americans being sold? Lancet. 2001; 358(9288):1141-1146. (Pubitemid 32971847)
21. Kallen A, Woloshin S, Shu J, Juhl E, Schwartz L. Direct-to-consumer advertisements for HIV antiretroviral medications: a progress report. Health Aff (Millwood). 2007;26(5):1392-1398.
22. 22. Kaphingst KA, Dejong W, Rudd RE, Daltroy LH. A content analysis of direct-to-consumer television prescription drug advertisements. J Health Commun. 2004;9(6):515-528. (Pubitemid 40115880)
23. 3. Kaphingst KA, Rudd RE, Dejong W, Daltroy LH. Literacy demands of product information intended to supplement television direct-to-consumer prescription drug advertisements. Patient Educ Couns. 2004;55(2):293-300.
24. Cuny TJ, Jarosch J, Pacholok S. Are direct-to-consumer advertisements of prescription drugs educational? Comparing 1992 to 2002. J Drug Educ. 2005; 35(3):217-232.
25. Chao BA. Evaluating the educational content of direct-to-consumer fulfillment materials. AmJ Health Syst Pharm. 2005; 62(6):620-625.
26. Huh J, Cude BJ. Is the information "fair and balanced" in direct-to-consumer prescription drug websites? J Health Commun. 2004;9(6):529-540.
27. Davis JJ, Cross E, Crowley J. Pharmaceutical website and the communication of risk information. J Health Commun. 2007;12(1);29-39.
28. 28. Kaphingst KA, Rudd RE, Dejong W, Daltroy LH. Comprehension of information in three direct-to-consumer television prescription drug advertisements among adults with limited literacy. J Health Commun. 2005;10(7):609-619. (Pubitemid 43154603)
29. Day RS; US Food and Drug Administration, Center for Drug Evaluation and Research. Comprehension of benefits vs. risks: fair balance in DTC? Available at: http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm175841.htm.January 11, 2005. Accessed October 16, 2008.
30. Glinert LH, Schommer JC. Television advertisement format and the provision of risk information about prescription drug products. Res Social Adm Pharm. 2005; 1(2):185-210.
31. Schommer JC, Doucette WR, Mehta BH. Rote learning after exposure to a direct-to-consumer television advertisement for a prescription drug. Clin Ther. 1998;20(3):617-632.
32. 32. Woloshin S, Schwartz LM, Welch HG. The value of benefit data in direct-to-consumer drag ads. Health Aff (Millwood). 2004(Suppl Web Exclusives): W4-234-245. (Pubitemid 39302586)
33. 33. Schwartz LM, Woloshin S, Welch HG. The drug facts box: providing consumers with simple tabular data on drug benefit and harm. Med Decis Making. 2007;27(5):655-662. (Pubitemid 47547602)
34. Sumpradit N, Fors SW, McCormick L. Consumers' attitudes and behavior toward prescription drug advertising. Am J Heath Behav. 2002;26(1):68-75.
35. Weissman JS, Blumenthal D, Silk AJ, Zapert K, Newman M, Leitman R. Consumers' reports on the health effects of direct-to-consumer drug advertising. Health Aff (Millwood). 2003(Suppl Web Exclusives) :W3-82-95.
36. Hoek J, Maubach N. Consumers' knowledge, perceptions, and responsiveness to direct-to-consumer advertising of prescription medicines. N Z Med J. 2007;120(1249):U2425.
37. Koch YdeS, Ernst ME, Kelly MW. Patient perceptions about drug advertising and prescription-to-nonprescription switches. AmJHealth Syst Pharm 2002;59(16):1568.
38. Mastin T, Andsager JL, Choi J, Lee K. Health disparities and direct-to-consumer prescription drug advertising: a content analysis of targeted magazine genres, 1992-2002. Health Commun. 2007; 22(1):49-58.
39. Parnes B, Smith PC, Gilroy C, et al. Lack of impact of direct-to-consumer advertising on the physician-patient encounter in primary care: a SNOCAP report. Ann Fam Med. 2009;7(1):41-46.
40. Welch Cline RJ, Young HN. Marketing drugs, marketing health care relationships: a content analysis of visual cues in direct-to-consumer prescription drug advertising. Health Commun. 2004;16(2):131-157.
41. Omonuwa SC. Health, disparity in Black women: lack of pharmaceutical advertising in Black- vs. White-oriented magazines. J Natl Med Assoc. 2001; 93(7-8):263-266.
42. Maubach N, Hoek J. New Zealand general practitioners' views on direct-to-consumer advertising of prescription medicines: a qualitative analysis. N Z Med J. 2005;118(1215):U1461.
43. Burak LJ, Damico A. College students' use of widely advertised medications. J.Am Coll Health 2000;49(3):118-121.
44. White HJ, Draves LP, Soong R, Moore C. 'Ask your doctor!' Measuring the effect of direct-to-consumer communications in the world's largest healthcare market. International J of Advertising. 2004;23:53-68.
45. 45. Zachry WM III, Dalen JE, Jackson TR. Clinicians' responses to direct-to-consumer advertising of prescription medications. Arch Intern Med 2003; 163(15):1808-1812. (Pubitemid 36960928)
46. Bell RA Wilkes MS, Kravitz RL. Advertisement-induced prescription drug requests: patients' anticipated reactions to a physician who refuses. J Fam Pract. 1999;48(6):446-452.
47. 47. Kravitz RL, Epstein RM, Feldman MD, et al. Influence of patients' requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA 2005;293( 16): 1995-2002. (Pubitemid 40570893)
48. 48.DonohueJM,BerndtER,RosenthalM,EpsteinAM,FrankRG. Effectsofpharmaceuticalpromotiononadherence-thetreatmentguidelinesfordepression. MedCare.2004;42(12):1176-1185.(Pubitemid39627294)
49. Meade-D'Alisera P, Merriweather T, Wentland M. Impact of commercial marketing on patient demand. Urol Nurs. 2001;21(6):406-407, 410.
50. 50.HollonMF,LarsonEB,KoepsellTD,DownerAE.Direct-to- consumermarketingofosteoporosisdrugsandbonedensitometry.AnnPharmacoiher. 2003;37(7-8):976-981.(Pubitemid36875224)
51. Johnson JA, Bootman JL. Drugrelated morbidity and mortality. A cost-of-illness model. Arch Intern Med. 1995;155(18):1949-1956.
52. 52. Wosinska M. Direct-to-consumer advertising and drug therapy compliance. J Mark Res. 2005;42(3):323-332. (Pubitemid 41251284)
53. 53. Bradford WD, Kleit AN, Nietert PJ, Ornstein S. Effects of direct-to-consumer advertising of hydroxymethylglutaryl coenzyme a reductase inhibitors on attainment of LDL-C goals. Clin Ther. 2006; 28(12):2105-2118. (Pubitemid 46223511)
54. Adams C. FDA to review policy allowing drug ads on TV. Wall Street Journal. March 28, 2001:B1.
55. 55.MintzesB,BarerML,KravitzRL,etal.Howdoesdirect-to- consumeradvertising(DTCA)affectprescribing? AsurveyinprimarycareenvironmentswithandwithoutlegalDTCA.CMAJ.2003;169(5): 405-412.(Pubitemid37076252)
56. Spence MM, Teleki SS, Cheetham TC, Schweitzer SO, Millares M. Direct-to-consumer advertising of COX-2 inhibitors: effect on appropriateness of prescribing. Med Care Res Rev. 2005; 62(5):544-559.
57. Hansen RA, Shaheen NJ, Schommer JC. Factors influencing the shift of patients from one proton pump inhibitor to another: the effect of direct-to-consumer advertising. Clin Ther. 2005;27(9): 1478-1487.
58. McDonagh MS, Carson S. Drug class review on proton pump inhibitors. Available at: http://derp.ohsu.edu/final/PPI%20final%20report-update%205- version%204-uashaded-09-May.pdf. Published 2006. Accessed October 2, 2008.
59. Conrad P, Leiter V. Medicalization, markets and consumers. J Health Soc Behav. 2004;45(Suppl):158-176.
60. 60.MintzesB.Forandagainst:direct- consumeradvertisingismedicalisingnormalhumanexperience:For.BMJ2002;324(7342): 908-909.(Pubitemid34303948)
61. 61.BonaccorsoSN,SturchioJLForandagainst:direct- consumeradvertisingismedicalisingnormalhumanexperience:Against.BMJ. 2002;324(7342):910-911.(Pubitemid34303949)
62. Arney J, Rafalovich A. Incomplete syllogisms as techniques of medicalization: the case of direct-to-consumer advertising in popular magazines, 1997 to 2003. Qual Health Res. 2007;17(1):49-60.
63. Bell RA, Kravitz RL, Wilkes MS. Direct-to-consumer prescription drug advertising, 1989-1998. A content analysis of conditions, targets, inducements, and appeals. J Fam Pract. 2000;49(4):329-335.
64. Davis JJ. Consumers' preferences for the communication of risk information in drug advertising. Health Aff (Millwood). 2007;26(3):863-870.
65. Halvorsen PA, Kristiansen IS. Decisions on drug therapies by numbers needed to treat: a randomized trial. Arch Intern Med. 2005;165(10):1140-1146.
66. Sheridan. SL, Pignone MP, Lewis CL. A randomized comparison of patients' understanding of number needed to treat and other common risk reduction formats. J Gen Intern Med 2003:18(11); 884-892.
67. Grimes T. Mild auditory-visual dissonance in television news may exceed viewer attentional capacity. Hum Commun Res. 1991;18(2):268-298.
68. Gencarelli DM. Average Wholesale Price for Prescription Drugs: Is There a More Appropriate Pricing Mechanism? Washington DC: National Health Policy Forum; 2002. Issue Brief 775.
69. Saul S. Celebrex commercial draws criticism. New York Times. October 4, 2007. Available at: http://www.nytimes.com/2007/04/10/business/media/1Ocelebrex. web.html?scp=1&sq=celebrex%20commercial%20draws%20criticism&st=cse. Accessed October 2, 2008.
70. Huff D. How to Lie With Statistics. New York, NY: WW Norton; 1993.
71. 71. Drazen JM. The consumer and the learned intermediary in health care. N Engl J Med. 2002;346(7):523-524. (Pubitemid 34441746)
72. 72. Mechanic D, McAlpine DD, Rosenthal M. Are patients' office visits with physicians getting shorter? N Engl J Med 2001;344(3):198-204. (Pubitemid 32065738)
73. 73. Tai-Seale M, McGuire TG, Zhang W. Time allocation in primary care office visits. Health Serv Res. 2007;42(5): 1871-1894. (Pubitemid 47397177)
74. Shah MB, Bentley JP, McCaffrey DJ III. Evaluations of care by adults following a denial of an advertisement-related prescription drug request: the role of expectations, symptom severity, and physician communication style. Soc Sci Med. 2006;62(4):888-899.
75. Freudenheim M. Showdown looms in Congress over drug advertising on TV. New York Times. January 22, 2007:C1.